prevacid sleep

Results Presented at American College of Neuropsychopharmacology Annual Meeting MARLBOROUGH, Mass.-- Sepracor Inc.(Nasdaq: SEPR) today announces the presentation of results from a Phase IV, 595-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and safety of LUNESTA([R]) brand eszopiclone in patients with insomnia and co-existing Generalized Anxiety Disorder (GAD). The results will be presented today at the annual meeting of the American College of Neuropsychopharmacology in Hollywood, Fla. Most Popular 10 Jobs That Pay $30 An Hour 13 Job Interview Mistakes To Avoid Today's Best Part-Time Jobs 5 Regular Mistakes In Public Speaking 3 Questions No Job Seeker Ever Wants To Be Asked? In this study, patients who met DSM-IV([R]1) criteria for both insomnia and GAD were randomized to receive nightly LEXAPRO([R])brand escitalopram oxalate 10 mg, which is approved for the treatment of GAD, and either LUNESTA 3 mg (n=294) or placebo (n=301) for the first eight weeks, followed by a two-week period in which patients discontinued study drug but continued receiving escitalopram and placebo. pricing of prevacid effects frequent prevacid pregnancy and prevacid effects longterm prevacid